Dimerix Ltd
Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company focused on developing new therapies for kidney diseases.
The business
Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company focused on developing new therapies for kidney diseases. The Company's lead program, DMX-200, is in Phase III clinical development for focal segmental glomerulosclerosis (FSGS), a serious and life-threatening rare kidney disease with limited treatment options. In addition, it is advancing a Phase II program in acute kidney injury (AKI), further strengthening its pipeline in high-need renal indications. DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. The Company's DMX-652 is a selective inhibitor of USP30 - a mitochondrial enzyme that slows the removal of damaged mitochondria. The Phase II trial is designed to investigate DMX-652's potential to prevent kidney injury and preserve renal function. It is also developing DMX-700 for respiratory disease.
Small Caps Research
No research on Dimerix Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise DXB based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Dimerix Secures Non-Dilutive Funding for Key Kidney Disease Programs
Dimerix secures up to A$34m non-dilutive funding to progress two kidney programs; half drawn now, funding ACTION3 Phase 3 and DMX-652 Phase 2.
Dimerix Expands Kidney Pipeline With Phase 2-Ready Acquisition
Dimerix expands kidney pipeline with DMX-652 acquisition; Phase 2-ready AKI therapy targets US$3.5b market, upfront US$5m plus up to US$292m milestones.
Dimerix Engages Everest Medicines to Commercialise DMX-200 Kidney Disease Treatment across Asia
Dimerix inks exclusive DMX-200 FSGS deal with Everest in Asia; upfront $14.1m, potential milestones up to ~$466m and 15% royalties.
Dimerix Completes Adult Dosing for ACTION3 DMX-200 Trial
Dimerix completes adult dosing for ACTION3 DMX-200 in FSGS; 333 patients vs 286 target, boosting statistical power and de-risking regulatory submission.
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.